Tempest Therapeutics, Inc. (TPST) — Insider Trading

AI-Powered SEC Filing Analysis

← All TPST filings
Latest Insider Trading Filed: 2026-03-25

Key Insights

  • Matthew Angel, the CEO and President of Tempest Therapeutics, Inc., has acquired 231,482 shares of the company's common stock at a price of $2.16 per share, indicating his confidence in the company's future.
  • Angel owns a significant stake of 4,837,070 direct shares in the company, representing his substantial investment and alignment with shareholder interests.
  • The filing also discloses that Angel indirectly owns shares through his position as the CEO and chairman of the board of Factor Bioscience Inc., which holds an additional 231,482 shares.
Filing tone (AI): Positive
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-25. In the app, any new 10-K, 10-Q or 8-K is analyzed the moment you open it.

Download on theApp Store Get it onGoogle Play
Get it on Google Play Open in app →

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.